Cochlear (ASX:COH) First Half 2025 Results

Key Financial Results

• Revenue: AU$1.17b (up 6.7% from 1H 2024).
• Net income: AU$205.1m (up 7.2% from 1H 2024).
• Profit margin: 18% (in line with 1H 2024).
• EPS: AU$3.13 (up from AU$2.92 in 1H 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cochlear Revenues Disappoint

Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia.

Performance of the Australian Medical Equipment industry.

The company's shares are down 15% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Cochlear's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.